$451.1 M

FPRX Mkt cap, 04-Dec-2018
Five Prime Therapeutics Net income (Q2, 2018)-34.1 M
Five Prime Therapeutics EBIT (Q2, 2018)-35.6 M
Five Prime Therapeutics Cash, 30-Jun-201852.8 M

Five Prime Therapeutics Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

R&D expense

32.8m70.2m94.1m150.9m

General and administrative expense

10.4m22.6m35.8m40.0m

Operating expense total

43.2m92.8m129.9m190.9m

EBIT

(29.4m)287.0m(99.2m)(151.4m)

Interest income

62.0k487.0k2.5m3.0m

Pre tax profit

287.5m(96.7m)(148.5m)

Income tax expense

(37.8m)31.0m(1.7m)

Net Income

(28.9m)249.6m(65.7m)(150.2m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

8.2m8.9m11.9m9.8m13.3m24.7m18.3b22.2b23.9m33.8m41.7m42.7m43.6m33.4m

General and administrative expense

2.6m3.3m3.0m3.4m4.6m5.2m8.6b8.1b9.1m10.5m9.4m9.7m10.5m9.8m

Operating expense total

10.8m12.2m14.9m13.2m17.9m29.9m26.9b30.3b33.0m44.2m51.1m52.4m54.0m43.2m

EBIT

(7.3m)(8.7m)(9.9m)(7.1m)(11.6m)(24.1m)(20.4b)(21.1b)(26.4m)(34.1m)(43.3m)(44.1m)(21.5m)(35.6m)

Interest income

7.0k36.0k55.0k57.0k117.0k107.0k536.0m646.0m639.0k668.0k702.0k792.0k1.2m1.5m

Pre tax profit

(19.9b)(20.4b)(25.7m)(33.4m)(42.6m)(43.3m)(20.4m)(34.1m)

Income tax expense

6.8b7.3b6.3m(1.7m)

Net Income

(7.2m)(8.6m)(9.9m)(7.1m)(11.5m)(24.0m)(13.0b)(13.1b)(19.4m)(33.4m)(44.3m)(43.3m)(20.4m)(34.1m)

Five Prime Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.2m15.3m150.0m7.7m59.8m

Accounts Receivable

Inventories

Current Assets

77.7m151.3m528.3m440.1m311.2m

PP&E

3.7m3.8m4.5m6.2m30.8m

Total Assets

81.8m155.6m548.3m448.3m344.0m

Accounts Payable

348.0k1.1m1.9m334.0k2.2m

Short-term debt

Current Liabilities

13.8m19.8m79.4m38.7m51.0m

Long-term debt

Total Debt

Common Stock

17.0k

Preferred Stock

Additional Paid-in Capital

209.6m274.2m372.6m396.6m421.3m

Retained Earnings

(151.6m)(189.0m)60.6m(5.0m)(155.6m)

Total Equity

58.0m433.2m391.6m265.2m

Financial Leverage

1.4 x1.3 x1.1 x1.3 x

Five Prime Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.9m)(37.4m)249.6m(65.7m)(150.2m)

Depreciation and Amortization

1.7m1.6m1.7m1.7m2.5m

Accounts Receivable

Inventories

Accounts Payable

(209.0k)701.0k798.0k(1.6m)1.9m

Cash From Operating Activities

(25.3m)15.3m289.1m(79.8m)(112.2m)

Purchases of PP&E

(807.0k)(1.6m)(2.4m)(3.0m)(4.9m)

Cash From Investing Activities

(42.2m)(69.4m)(238.2m)(53.7m)

Cash From Financing Activities

64.3m61.2m83.8m(8.9m)(9.9m)

Income Taxes Paid

11.4m1.7m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.5m)(24.0m)(13.0b)(13.1b)(19.4b)(33.4b)(43.3b)

Accounts Payable

3.8m347.0k767.0k672.0k904.0k1.4m1.6m1.0m654.0k528.0k807.0k1.3m2.9m

Five Prime Therapeutics Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information

Five Prime Therapeutics Employee Rating

2.333 votes
Culture & Values
2.5
Work/Life Balance
3.0
Senior Management
2.6
Salary & Benefits
3.1
Career Opportunities
2.5
Source